Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$35.01M$35.01Mno prior Q2 2016 on file Net Income-$63.05M-$63.05MN/M vs Q2 2016 EPS Diluted-$1.15-$1.15N/M vs Q2 2016 Operating Income-$63,339,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$88,018,000N/M Margins · derivedOperating margin-180.9%
Net margin-180.1%
ended Jun 30, 2017 · filed Aug 3, 2017 · 34 d after period end